Dodge & Cox Neurocrine Biosciences Inc Transaction History
Dodge & Cox
- $160 Billion
- Q4 2024
A detailed history of Dodge & Cox transactions in Neurocrine Biosciences Inc stock. As of the latest transaction made, Dodge & Cox holds 3,016,425 shares of NBIX stock, worth $364 Million. This represents 0.26% of its overall portfolio holdings.
Number of Shares
3,016,425
Previous 1,287,820
134.23%
Holding current value
$364 Million
Previous $148 Million
177.7%
% of portfolio
0.26%
Previous 0.09%
Shares
6 transactions
Others Institutions Holding NBIX
# of Institutions
654Shares Held
96.5MCall Options Held
282KPut Options Held
281K-
Black Rock Inc. New York, NY14.2MShares$1.71 Billion0.04% of portfolio
-
Vanguard Group Inc Valley Forge, PA10.1MShares$1.22 Billion0.02% of portfolio
-
State Street Corp Boston, MA4.89MShares$590 Million0.03% of portfolio
-
Ken Griffin Citadel Advisors LLC | Chicago, Il2.54MShares$306 Million0.06% of portfolio
-
Jim Simons Renaissance Technologies LLC | New York, Ny2.49MShares$300 Million0.54% of portfolio
About NEUROCRINE BIOSCIENCES INC
- Ticker NBIX
- Exchange NASDAQ
- Sector Healthcare
- Industry Drug Manufacturers—Specialty & Generic
- Shares Outstandng 95,639,296
- Market Cap $11.5B
- Description
- Neurocrine Biosciences, Inc. discovers, develops, and markets pharmaceuticals for neurological, endocrine, and psychiatric disorders. The company's portfolio includes treatments for tardive dyskinesia, Parkinson's disease, endometriosis, and uterine fibroids, as well as clinical programs in various therapeutic areas. Its lead asset is INGREZZA, ...